Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line. (17th February 2018)

• Record Type: Journal Article
• Authors: Shali, Hajar; Shabani, Mahdi; Pourgholi, Fatemeh; Hajivalili, Mahsa; Aghebati-Maleki, Leili; Jadidi-Niaragh, Farhad; Baradaran, Behzad; Movassaghpour Akbari, Ali Akbar; Younesi, Vahid; Yousefi, Mehdi
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 46:Number 2(2018)
• Page Start: 293
• Page End: 302
• Publication Date: 2018-02-17
• Subjects: Chitosan nanoparticle -- doxorubicin -- IGF-1R -- lung cancer; ss siRNA; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2017.1307212
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: Here, we investigated the effects of dual delivery of IGF-1R siRNA and doxorubicin by chitosan nanoparticles on viability of A549 lung cancer cells line by utilization of MTT and qRT-PCR. Furthermore apoptosis and migration of treated cells were assessed by Annexin-PI and wound healing assays, respectively. The chitosan nanoparticles had about 176 nm size with zeta potential and polydispersive index about 11 mV and 0.3, respectively. The IGF-1R siRNA had synergistic effect on DOX-induced cytotoxicity and apoptosis in tumour cells. In addition, siRNA/DOX-loaded chitosan nanoparticles could significantly decrease migration and expressions of mmp9, VEGF and STAT3 in A549 cells.